Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual-tracer PET/CT identifies an aggressive PSMA-negative/FDG-positive phenotype predicting early failure of radical prostatectomy in treatment-naive prostate cancer.

European journal of nuclear medicine and molecular imaging - 1 Mar 2026

Chen Ruohua, Wang Yining, Chen Qiaochu, Dong Liang, Huang Gang, Liu Jianjun

Abstract excerpt

BACKGROUND AND PURPOSE: The metabolic phenotype of negative prostate-specific membrane antigen (PSMA) and positive [18F]F-fluorodeoxyglucose ([18F]F-FDG) uptake is an established indicator of unfavorable prognosis in advanced-stage prostate cancer. It is also associated with resistance to PSMA-targeted therapies. However, its prognostic significance in the preoperative setting for treatment-naive patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antigens, Surface

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorodeoxyglucose F18

Share to Phenotype

Share to Positron Emission Tomography Computed Tomography

Share to Prostatectomy

Share to Prostatic Neoplasms

Share to Treatment Failure

Source

Identifiers

PMID: 41212260
DOI: 10.1007/s00259-025-07646-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual-tracer PET/CT identifies an aggressive PSMA-negative/FDG-positive phenotype predicting early failure of radical prostatectomy in treatment-naive prostate cancer.PMID 41212260Read ↗

Dual-Tracer 18 F-FDG and 68 Ga-PSMA PET/CT Imaging of Heterogeneous Phenotypes of Metastatic Castration-Resistant Prostate Cancer for Predicting Response to Novel Hormone Therapy.Semantic proximity Read ↗

When PSMA Is Not Enough: The Diagnostic Blind Spots of PSMA PET/CT and the Added Value of [¹⁸F]FDG in High-Risk Prostate Cancer: Dual-Tracer Cohort StudySemantic proximity Read ↗

Usefulness of Tissue Biomarkers versus Prostate-Spcific Membrane Antigen-Positron Emission Tomography for Prostate Cancer Biochemical Recurrence after Radical ProstatectomySemantic proximity Read ↗

Beyond PSMA: The essential complementary role of MRI in staging prostate cancer with Low-PSMA expression phenotypes.Semantic proximity Read ↗

Multimodal Radiogenomic Machine Learning for Biochemical Recurrence Prediction Following Radical Prostatectomy Using PSMA-PET, mpMRI, and the Decipher Genomic ClassifierSemantic proximity Read ↗

Bivariate Diagnostic Paired Meta-Analysis at the Patient Level: Direct Validation of PSMA-PET against Conventional Imaging Across All T/N/M Staging Dimensions in Primary Intermediate- to High-Risk Prostate CancerSemantic proximity Read ↗

Patterns of disease detection using 18F-DCFPyL PET/CT imaging in men with biochemical recurrence post prostatectomy being considered for salvage radiotherapy: a prospective trialSemantic proximity Read ↗

Follow-up Analysis of Intermediate-risk Prostate Cancer Patients Staged With Psma PET/CTSemantic proximity Read ↗

Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for <sup>18</sup>F-FDG Imaging of PSMA-Suppressed TumorsSemantic proximity Read ↗

Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer.Semantic proximity Read ↗

Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer.Semantic proximity Read ↗

Metabolic and imaging phenotypes associated with RB1 and TP53 loss in prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.